ASPIRE BIOPHARMA HOLDIN-CW27(NASDAQ:ASBPW) stock News

ASBPW Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

a month ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

a month ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

2 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

2 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

2 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

3 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

3 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

5 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

3 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

3 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

4 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

4 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

5 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

5 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

5 months ago - By: ACCESS Newswire - Mentions: PWUP ASBP

ASPIRE BIOPHARMA HOLDIN-CW27 (ASBPW) Stock News

ASBPW Latest News, Press Relases and Analysis

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq